ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Celligenics Logo

Celligenics

At Celligenics, we are reinventing the way forward by harnessing regenerative technology to support the body in repairing, regenerating, and restoring itself to a state of well-being. Established in 2016, Celligenics is a spin-off of the Agency for Science, Technology & Research (A*STAR), Singapore’s leading public R&D agency, and one of A*STAR’s top 10 new biotech start-ups in 2018. We are also a finalist for Singapore’s Emerging Enterprise Award 2021, the top business award jointly organised by OCBC Bank and The Business times that recognises the ambitions of emerging enterprises. Celligenics Announces China Market Entry, & Signs MOU With West China Hospital. Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021). Our regenerative extract is a platform technology, with limitless application potential. Two product lines are currently under development, with more to come. Traditional skincare products lose their effectiveness over time, and stronger and more expensive products are then required to maintain the health of our skin.

Quick overview

San Jose, Philippines

Founded in 2016

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

-

Ownership structure

Privately Held

Locations

1 Headquarter

Specialised areas

Biotechnology

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

Philippines


Overall risk estimation:

High


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

C

Grade (A-E)

View details

Governance

D

Grade (A-E)

View details

Headquarter of Celligenics

Celligenics operates in 1 country around the world

City: San Jose

State: Nueva Ecija

Country: Philippines

Locations of Celligenics

Get an overview of the locations of Celligenics

Location

Country

State

City

Headquarter

Philippines

Nueva Ecija

San Jose

Frequently asked questions (FAQ) about Celligenics

Some frequent questions that have been asked about Celligenics

The company headquarter of Celligenics is located in San Jose, Nueva Ecija, Philippines. It's worth noting, that the company may have more locations

As of the latest available information Celligenics has around 11-50 employees worldwide.

Celligenics was founded in 2016

The company Celligenics has it's main focus in the industries of Biotechnology

Competitors of Celligenics

Check out some interesting alternative companies to Celligenics

CellResearch Corporation's Logo

CellResearch Corporation

San Jose, Philippines

1-10 Employees

2002

CellResearch Corporation was founded in Singapore in 2002 by scientists with a keen interest and expertise in Cell Biology. It’s original remit was to provide skin and scar cells to laboratories around the world for research, as well as to perform contract research for skin research laboratories internationally. Do not compromise on your future with unlicensed techniques or banking providers. CALECIM® Cosmeceuticals Pte Ltd is a skin care company based on CALECIM®.

BioGenCell's Logo

BioGenCell

Netanya, Israel

1-10 Employees

2008

Our mission is to make personalized cell therapy a reality for patients worldwide, providing accessible treatments to various unmet needs. Meet the people behind BioGenCell: A Group of Dedicated BioMed, Healthcare, Vascular and Business Professionals, Including a Nobel Prize Laureate and World-Renowned Scientists. BioGenCell is dedicated to changing the lives of patients suffering from degenerative microvascular diseases, stopping disease progression, reversing disability, reducing pain, and enhancing functionality. BioGenCell’s groundbreaking cell-therapy treatments aim to provide more accessible, reliable and cost-effective therapeutic options, with the hope of significantly impacting these tragic figures. BioGenCell’s Phase 2 Clinical Trial assesses the safety and efficacy of the BGC101 cell therapy in treating Chronic Limb-Threatening Ischemia. Since its inception in 2008, BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments, based on the Company’s groundbreaking TRACT technology that uses a patient’s own blood as personalized medicine. Our innovative TRACT technology allows for stem cell therapies that are patient-friendly and physician-friendly. Through advanced, standardized procedures, we are dedicated to bringing transformative cell therapy treatments to vascular physicians and surgeons, podiatrists, and various other healthcare providers and clinicians.

Re-gen Active Lab's Logo

Re-gen Active Lab

Irving, United States

11-50 Employees

2018

All our products are developed in our own cutting edge ISO Class 3 laboratory facility by highly trained scientists and engineers. We are proud to have developed stem cell-derived products from a minimally manipulated eligible human umbilical cord and placenta tissue without a combination of any other articles that raise new clinical safety concerns with respect to our products. Our products contain stem cell-derived bio-active biomolecules, cell fragments, cell contents, and its extracellular matrix. This makes our products stand out in the market for two main reasons. First, our products contain stem cells derived bioactive biomolecules that act as a signals to initiate tissue regeneration within minutes of administration, and second, we are fully compliant with Section 361 of the PHS Act and FDA 21CFR 1271 by not including an intact live cell in our products but all the components of it. We are here to help, and our products may assist your body to repair itself. Re-gen Active Lab is an Irving, Texas, based Biotechnology Company established in 2018 with a goal of revolutionizing regenerative medicine through the development of novel stem cell therapy for wound healing, regeneration, anti-inflammatory, and well-being applications. We have total control over all the steps involved in our product development process to achieve high levels of safety, purity, potency, viability, and reproducibility (batch to batch consistency).

StemGenn Therapeutics's Logo

StemGenn Therapeutics

India

11-50 Employees

2014

StemGenn is dedicated to advancing the field of regenerative medicine & Molecular Medicine by offering the highest quality technology, cellular therapy and training. StemGenn is committed to maintaining its leading position within the infertility sector of the cell technology industry by delivering stem cell therapies and biologics that help address Poor ovarian reserve, Asherman syndrome, Thin Endometrium, Erectile dysfunction, SUI , menopause management and other issues. StemGenn goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalisations. StemGenn leading procedure , Lipokraft, O-Cell PRP is a clinical adipose cell therapy & concentrated plasma designed to populate regions of scar tissue within a patient’s with new living cells for the purpose of improving function in degenerative conditions. We are an international med tech company that is focused in the field of stem cell & regenerative medicine. We are devoted to developing therapeutic products & services that have the potential to be safer and are more effective than the current standard of care. Our products and services are aimed at providing better treatment and management for the diseases leading to a better quality of life. StemGenn Therapeutics is a Biotechnology Company promoting disruptive regenerative medicines.

CELLnLIFE's Logo

CELLnLIFE

Kazan, Russia

- Employees

2018

CELLnLIFE Inc. is a company that develops immune disease treatments using IntenCell®, an efficacy-enhancing stem cell. Based on the independently developed S-I-S culture platform technology, we are striving to overcome therapeutic efficiency limitations of stem cell therapy, thereby delivering healthy life and wellness to suffering patients with unmet medical needs. We are constantly challenging ourselves and do our best to grow into a company that can lead the global stem cell therapy market, while maintaining strong corporate ethics. 8th floor 50, Digital-ro 33-gil, Guro-gu, Seoul, Republic of Korea.

S-Cell Health's Logo

S-Cell Health

Los Angeles, United States

1-10 Employees

-

S-CELL Health & Beauty uses cutting edge technology and the latest scientific breakthroughs to support the body's ability to rejuvenate a particular health concerns. S-CELL Health & Beauty, a brand of VitaCell International Co. Located in Hong Kong, S-CELL Health & Beauty's inspiration to provide the best of both worlds remains strong. S-CELL Health & Beauty aims to bring the finest in wellness through the fusion of the newest developments in cellular health and the use of natural and top-of-the-line ingredients for the purpose of enriching the quality of living, as exemplified by its first products that included NAD+ cellular boosters, Cell Revival and NAD Revival, which were the first to be sold in Asia and are now ready to be introduced to the rest of the world. S-CELL Health & Beauty is committed to provide products that are derived from natural ingredients and are proven safe and effective by scientific knowledge. Since the beginning of S-CELL Health & Beauty in 2016, the company has been riding the wave of human clinical results releases which have reinforced the breakthrough discovery of Dr. All ingredients used in S-CELL Health & Beauty's formulations are subjects of numerous clinical studies that have been recognized as the best nutraceutical ingredients by the industry authorities for the proven benefits to healthy aging. All of S-CELL Health & Beauty's products, which are manufactured in the United States and in the United Kingdom, have passed the stringent requirements of both the US Food and Drug Administration (FDA) and the British Retail Consortium (BRC) of the United Kingdom.